Search for: "MERCK & CO., INC. "
Results 81 - 100
of 674
Sort by Relevance
|
Sort by Date
17 Apr 2018, 8:33 am
Merck & Co. [read post]
11 Apr 2018, 10:49 am
Edison Co. v.NLRB, 305 U.S. 197, 229 (1938)). [read post]
6 Apr 2018, 10:25 am
Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. [read post]
17 Mar 2018, 7:18 am
” Nate Raymond of Reuters has a report that begins, “Massachusetts’ top court on Friday opened the door for consumers to sue Merck & Co Inc and other makers of brand-name drugs over injuries blamed not on their own medications but on generic versions of their treatments made by other companies. [read post]
27 Feb 2018, 12:24 pm
Industrial Co. v. [read post]
14 Feb 2018, 2:57 pm
ANZ Securities, Inc. [read post]
3 Feb 2018, 8:58 pm
Jorge Goldstein of Sterne, Kessler, Goldstein & Fox, PLLC; Brian Kacedon of Finnegan, Henderson, Farabow, Garrett & Dunner LLP; and William Krovatin of Merck & Co Inc. will discuss strategies and recent court cases that involve: • Staking out the claim that a sale is not an "authorized sale" — Chrimar v. [read post]
19 Dec 2017, 3:13 pm
Note the case Merck v. [read post]
1 Dec 2017, 11:35 am
Merck & Co is currently ranked No.1 in R&D, although it is fourth in sales. [read post]
15 Nov 2017, 12:34 pm
Merck & Co. v. [read post]
22 Oct 2017, 9:59 pm
Inc. [read post]
24 Jun 2017, 9:12 pm
Paul Jahn of Morrison & Foerster LLP; William Krovatin of Merck & Co., Inc.; and Richard Rainey of Covington & Burling LLP will explore the significant ramifications of the recent U.S. [read post]
16 Jun 2017, 9:44 am
This year's winners and technologies are: Merck & Co., Inc. in Greener Synthetic Pathways -- Letermovir: A Case Study in State-of-the-Art Approaches to Sustainable Commercial Manufacturing Processes in the Pharmaceutical Industry; Amgen Inc. and Bachem in Greener Reaction Conditions -- Green Process for Commercial Manufacture of Etelcalcetide Enabled by Improved Technology for Solid Phase Peptide Synthesis; The Dow Chemical… [read post]
12 Jun 2017, 3:18 pm
This year's winners and technologies are: Merck & Co., Inc. in Greener Synthetic Pathways - Letermovir: A Case Study in State-of-the-Art Approaches to Sustainable Commercial Manufacturing Processes in the Pharmaceutical Industry Merck’s approach was to design an efficient synthesis as early as possible in the drug Letermovir’s process development. [read post]
6 Apr 2017, 1:35 pm
Wells Electronics, Inc., 525 U.S. 55, 57–68 (1998).See Medicines Co. v. [read post]
3 Mar 2017, 7:25 am
The judge also cautioned that the purpose of the declarations in the present proceedings is different to the motivations for the declarations sought in Arrow Generics Limited v Merck & Co. [read post]
8 Feb 2017, 3:09 am
Extraterritoriality – Trade Secrecy: Sino Legend (Zhangjiagang) Chemical Co. [read post]
16 Jan 2017, 5:44 pm
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Anticipation/Obviousness: Merck & Cie, et al. v. [read post]
13 Jan 2017, 9:24 am
A declaration in these terms is described as an Arrow declaration, due to the form of relief sought in Arrow Generics Limited v Merck & Co. [read post]
5 Jan 2017, 2:15 am
On Thursday, December 15th, a subsidiary of Kenilworth, NJ-based pharmaceutical developer Merck & Co. [read post]
